Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 24.8 cents per share of common stock, a 5% increase over the previous dividend. The quarterly dividend will be paid on Jan. 22, 2025, to all shareholders of record as of the close of business on Dec. 31, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies A.

Agilent Increases Cash Dividend to 24.8 Cents per Share

Agilent Technologies Inc (NYSE:A) is scheduled to release fourth-quarter financial results after the close on Monday, Nov. 25.

What to Expect from Agilent's Quarterly Report

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Agilent (A), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended October 2024.

Stay Ahead of the Game With Agilent (A) Q4 Earnings: Wall Street's Insights on Key Metrics

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that Adeyemi Adeleye, Ph.D., has received the Agilent 2024 Early Career Professor Award for his contribution to environmental health and sustainability, developing green analytical technologies, methods, or laboratory working environments. Dr. Adeleye is an assistant professor in the Department of Earth and Environmental Engineering at Columbia University. The 2024 award focused on contributions to academi.

Agilent 2024 Early Career Professor Award Presented to Adeyemi Adeleye

CAMBRIDGE, England--(BUSINESS WIRE)--Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has entered into a strategic co-marketing agreement with Agilent Technologies, a leading tools provider in the genomics sector. The agreement offers select customers the opportunity to access Tagomics' and Agilent Technologies' combined innovative offerings through an exclusive technology access program hosted out of Tagomics' service lab in Cambridge. Tagomics has de.

Tagomics Announces a Multiomic Profiling Co-Marketing Agreement with Agilent

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company has been named to Fortune's list of Best Workplaces in the World, ranking no. 11 among 25 companies. The list is based on 7.4 million responses to the Great Place to Work survey, which represents the experiences of 20 million employees worldwide. The survey assesses employee satisfaction in key areas, from credibility and respect to fairness and camaraderie. “Being named one of the best workpla.

Agilent Ranks No. 11 on Fortune's List of Best Workplaces in the World

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announces the new Mito-rOCR Assay Kit. This easy and streamlined end-to-end solution makes sophisticated analysis of mitochondrial function available to researchers of all skill levels. With this cost-effective and versatile kit, researchers can easily incorporate functional assessment of relative mitochondrial respiration into their cell physiology and disease pathology studies. Mitochondria are central to energy product.

Agilent Announces the Innovative Mito-rOCR Assay Kit for Mitochondrial Research

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Professor Isabelle Plante at Institut National de la Recherche Scientifique (INRS), and Professor Bangyan Stiles at the University of Southern California (USC) are recipients of an Agilent Solutions Innovation Research Award (SIRA). The honorees will receive separate awards on behalf of their institutions in recognition of their research in cell and gene therapy. Developing new cell and gene therapies.

Agilent Presents Solutions Innovation Research Awards to Institut National de la Recherche Scientifique and University of Southern California Scientists

A's expanding LSAG portfolio may bode well for the stock, despite macroeconomic risks and stretched valuation.

Agilent Expands LSAG Segment: How Should You Approach the Stock?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all including the biocompatible versions. These are the first HPLC systems on the market to feature the new Agilent InfinityLab Assist Technology, offering enhanced, built-in system assistance capabilities. This technology allows.

Agilent Revolutionizes HPLC with the Launch of the Agilent Infinity III LC Series

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent will release financial results for the fourth quarter of fiscal year 2024 on Nov. 25.

Agilent to Announce Fourth-Quarter Fiscal Year 2024 Financial Results on Nov. 25

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will host an Analyst and Investor Day in New York City on Tuesday, Dec. 17, at 10 a.m. ET. CEO Padraig McDonnell, CFO Bob McMahon, and other senior business leaders will present information regarding Agilent's strategy, businesses, and long-term financial outlook. The event will conclude with a Q&A session. This in-person event is by invitation only, but a live webcast will be accessible through Agilent's Investor Rel.

Agilent to Host Analyst and Investor Day on Dec. 17, 2024

MIAMI--(BUSINESS WIRE)-- #Acquisition--H.I.G. Capital sold its portfolio company, BIOVECTRA Inc., to Agilent Technologies, Inc. (NYSE: A) for a purchase price of $925 million.

H.I.G. Capital Completes the Sale of BIOVECTRA

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Why Is Agilent (A) Up 1.2% Since Last Earnings Report?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization.

Agilent Completes Acquisition of BIOVECTRA

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 23.6 cents per share of common stock will be paid on Oct. 23, 2024, to all shareholders of record as of the close of business on Oct. 1, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory tec.

Agilent Announces Cash Dividend of 23.6 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc., (NYSE: A) today announced the launch of its Biopharma CDx Services Lab (BCSL) in Carpinteria, California, following receipt of California State clinical laboratory license and Clinical Laboratory Improvement Amendments (CLIA) certificate of compliance. These credentials signify that the lab operates in accordance with CLIA regulations, which are federal standards applicable to all U.S. facilities testing human specimens for health.

Agilent Unveils Biopharma CDx Services Lab to Accelerate Precision Medicine

Agilent Technologies Inc. NYSE: A is a diversified global leader in the life sciences, diagnostics, and applied chemical markets. The company provides equipment systems, instruments, software and services that enable researchers and scientists to make breakthroughs in the medical sector and various fields.

Agilent Technologies Thrives From the Forever Chemicals Crackdown

American Airlines

Boeing

General Electric

Engine repair shops have swelled to a $58 billion business, according to Alton Aviation Consultancy, and are cash cow for engine makers like GE Aerospace.

Airplane engines are in short supply. The business of fixing older ones is booming

Evaluate Agilent's (A) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Agilent (A) Reliance on International Sales: What Investors Need to Know

Agilent Technologies focuses on growing biopharma, PFAS testing, and advanced materials for semiconductors. Recent acquisitions and divestitures show mixed results, with potential for technological enhancement but concerns about fit in the portfolio. Despite challenges in the pharma market, Agilent's diversified revenue streams and potential for growth in key areas make it a 'Buy' with a target price of $160 per share.

Agilent: A 'Buy' Due To Growing Biopharma, PFAS, And Semi

Agilent's (A) fiscal third-quarter results reflect weakness across the Pharma, Food, Chemical and Advanced Materials, and Academic and Government markets.

Agilent (A) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y

Agilent Technologies, Inc. A posted better-than-expected third-quarter earnings and issued upbeat fourth-quarter guidance on Wednesday.

These Analysts Boost Their Forecasts On Agilent After Strong Earnings

Agilent Technologies (NYSE: A ) just reported results for the third quarter of 2024. Agilent Technologies reported earnings per share of $1.32.

A Stock Earnings: Agilent Technologies Beats EPS, Beats Revenue for Q3 2024

Agilent Technologies, Inc. (NYSE:A ) Q3 2024 Earnings Conference Call August 21, 2024 4:30 PM ET Company Participants Conference Call Participants Operator Ladies and gentlemen, welcome to the Agilent Technologies Q3 2024 Earnings Call. My name is Regina and I will be coordinating your call today.

News for Agilent Technologies Stock (A)